JP2003522786A - 薬理学的薬剤、及び治療の方法 - Google Patents

薬理学的薬剤、及び治療の方法

Info

Publication number
JP2003522786A
JP2003522786A JP2001559447A JP2001559447A JP2003522786A JP 2003522786 A JP2003522786 A JP 2003522786A JP 2001559447 A JP2001559447 A JP 2001559447A JP 2001559447 A JP2001559447 A JP 2001559447A JP 2003522786 A JP2003522786 A JP 2003522786A
Authority
JP
Japan
Prior art keywords
derivative
group
picolinic acid
chelating agent
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001559447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522786A5 (https=
Inventor
ポール ジョセ エー フエルナンデズ
アビンッシュ エヌ アミン
ミクハエル ジー ドウグラス
Original Assignee
ノバクチル インコーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバクチル インコーポレーション filed Critical ノバクチル インコーポレーション
Publication of JP2003522786A publication Critical patent/JP2003522786A/ja
Publication of JP2003522786A5 publication Critical patent/JP2003522786A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
JP2001559447A 2000-02-15 2001-02-15 薬理学的薬剤、及び治療の方法 Pending JP2003522786A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18260800P 2000-02-15 2000-02-15
US60/182,608 2000-02-15
PCT/US2001/004897 WO2001060349A2 (en) 2000-02-15 2001-02-15 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof.

Publications (2)

Publication Number Publication Date
JP2003522786A true JP2003522786A (ja) 2003-07-29
JP2003522786A5 JP2003522786A5 (https=) 2005-08-25

Family

ID=22669217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001559447A Pending JP2003522786A (ja) 2000-02-15 2001-02-15 薬理学的薬剤、及び治療の方法

Country Status (10)

Country Link
US (1) US6403618B1 (https=)
EP (1) EP1257262A2 (https=)
JP (1) JP2003522786A (https=)
AU (1) AU781066B2 (https=)
BR (1) BR0108400A (https=)
DE (1) DE01909253T1 (https=)
ES (1) ES2215493T1 (https=)
MX (1) MXPA02007954A (https=)
TR (1) TR200301378T3 (https=)
WO (1) WO2001060349A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074063A1 (en) * 1995-12-29 2006-04-06 Fernandez-Pol Jose A Pharmacological agent and method of treatment
US6579891B1 (en) * 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
EP1420786A2 (en) * 2001-08-23 2004-05-26 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Methods of inhibiting formation of vascular channels and proliferation using pyridinone derivatives
WO2003055477A1 (en) * 2001-12-21 2003-07-10 7Tm Pharma A/S Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
EP2075014B9 (en) 2002-05-24 2012-02-01 Angiotech International Ag Compositions and methods for coating medical implants
CA2536192A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Soft tissue implants and anti-scarring agents
ES2702607T3 (es) * 2004-01-07 2019-03-04 E L Man Corporation Composición cosmética y método de retardo del crecimiento del vello
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
US20070178062A1 (en) * 2005-10-07 2007-08-02 Nathan Ravi Treatment of presbyopia with picolinic acid and its analogs
WO2007048051A2 (en) * 2005-10-20 2007-04-26 Viamet Pharmaceuticals, Inc. Screening for modulators of metalation pathways for metalloproteins
WO2011041680A2 (en) 2009-10-02 2011-04-07 The Brigham And Women's Hospital, Inc. Compositions and methods of prophylaxis for contact dermatitis
GB201317619D0 (en) 2013-10-04 2013-11-20 Uni I Oslo Compounds
JP6843225B2 (ja) * 2016-07-28 2021-03-17 チャンスー ヤホン メディテック カンパニー リミテッド 癌の処置のためのドーパミンβ−ヒドロキシラーゼ（ＤＢＨ）阻害剤およびセロトニン受容体（５−ＨＴ）アンタゴニストの使用
GB201613946D0 (en) 2016-08-15 2016-09-28 Univ Oslo Compounds

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903285A (en) 1972-12-29 1975-09-02 Microbial Chem Res Found Method for treating parkinsonism
ZA767103B (en) 1975-11-28 1977-10-26 Scherico Ltd Picolinic acid derivatives and processes for their preparation
CH629488A5 (en) 1975-11-28 1982-04-30 Scherico Ltd Processes for preparing novel picolinic acid derivatives.
US4044140A (en) 1975-11-28 1977-08-23 Schering Corporation Trityl picolinic acid derivatives and their use as anti-acne agents
US4120762A (en) 1977-09-30 1978-10-17 Alden Research Foundation Electrochemical recording medium
US4293547A (en) 1980-08-25 1981-10-06 The Upjohn Company Method of treating malaria
US4443459A (en) 1981-05-26 1984-04-17 Banyu Pharmaceutical Co., Ltd. α-Tocopheryl ester of 5-substituted picolinic acid and hypotensive composition containing it
US4814351A (en) 1987-06-26 1989-03-21 Redken Laboratories, Inc. Scalp treatment
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5057320A (en) 1988-08-01 1991-10-15 Nutrition 21 Means and method for increasing skin respiration
US5157046A (en) 1988-11-29 1992-10-20 Janssen Pharmaceutica N.V. Method of treating epithelial disorders
US5219847A (en) 1989-06-12 1993-06-15 Shiseido Company, Ltd. Antipruritic composition
FR2657259A1 (fr) 1990-01-25 1991-07-26 Adir Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5403816A (en) 1990-10-25 1995-04-04 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative and herbicidal composition
US5391537A (en) 1990-10-25 1995-02-21 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative, and herbicidal composition
US5173486A (en) 1991-08-26 1992-12-22 Bristol-Myers Squibb Company Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents
US5516941A (en) 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
IL104323A0 (en) 1992-01-10 1993-05-13 Smithkline Beecham Corp Hemoregulatory peptides
US5284840A (en) 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5962463A (en) * 1992-10-09 1999-10-05 Massachusetts Institute Of Technology Methods of stimulating non-amyloidogenic processing of the amyloid precursor protein
WO1994027627A1 (en) 1993-05-24 1994-12-08 Smithkline Beecham Corporation Hemoregulatory peptides
US6001555A (en) 1994-09-23 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein
FR2736263B1 (fr) 1995-07-07 1997-09-26 C3D Sarl Composition dermocosmetique depigmentante et son utilisation
US5767135A (en) 1995-12-29 1998-06-16 Fernandez-Pol; Jose Alberto Antiviral agent
JP3337992B2 (ja) 1997-11-04 2002-10-28 ファイザー製薬株式会社 ５−置換ピコリン酸化合物及びその製造方法

Also Published As

Publication number Publication date
WO2001060349B1 (en) 2001-12-27
BR0108400A (pt) 2003-03-11
DE01909253T1 (de) 2004-04-15
ES2215493T1 (es) 2004-10-16
AU3702801A (en) 2001-08-27
AU781066B2 (en) 2005-05-05
US6403618B1 (en) 2002-06-11
WO2001060349A2 (en) 2001-08-23
TR200301378T3 (tr) 2003-12-22
EP1257262A2 (en) 2002-11-20
MXPA02007954A (es) 2004-09-10
WO2001060349A3 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
US6127393A (en) Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6579891B1 (en) Agent and method for prevention and treatment of cancer in animals
US5767135A (en) Antiviral agent
US6407125B1 (en) Pharmacological agent and method of treatment
US20060074063A1 (en) Pharmacological agent and method of treatment
AU783015B2 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
JP2003522786A (ja) 薬理学的薬剤、及び治療の方法
JP2505944B2 (ja) （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
JPH07505378A (ja) 線維障害の創傷治療処置
CN105143174A (zh) 治疗帕金森疾病的新型高穿透力药物和医药组合物
WO2014008248A2 (en) Compositions and methods for treating and inhibiting viral infections
KR20180100309A (ko) 데옥시콜산 및 이의 염을 사용한 축적된 지방의 치료 방법
Cutler et al. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus
US6441009B1 (en) Agent and method of preventing and treating heavy metal exposure and toxicity
WO2022206086A1 (zh) 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用
US20140011839A1 (en) Compositions and methods for treating and inhibiting viral infections
US20170296530A1 (en) Compositions and Methods for Treating and Inhibiting Viral Infections
JPS5877824A (ja) インターフェロンを含む組成物
KR100302994B1 (ko) 약독화된비면역원성폭스바이러스또는파라폭스바이러스로부터멀티포텐트파라폭스면역유발인자의약제로서이용하는새로운적용
US20140011837A1 (en) Compositions and methods for treating warts associated with viral infections
TW202339711A (zh) 預防或治療心血管疾病的高穿透性的阿司匹靈和其他非類固醇抗發炎藥的前藥
WO2022123323A1 (en) A pharmaceutical composition of artesunate and mefloquine and method thereof
CN117323418B (zh) 一种含乳铁蛋白的胶囊在阻止hpv病毒感染中的用途
CN100558363C (zh) 一种治疗尖锐湿疣的药物组合物
RU2681546C1 (ru) Способ экстренной профилактики клещевого вирусного энцефалита

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060609

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20061110